Pyruvate dehydrogenase kinase 4 in acute kidney injury and the acute kidney injury‑to‑chronic kidney disease transition: A key metabolic regulatory hub and potential therapeutic target (Review)

Acute kidney injury (AKI) is a common and heterogeneous clinical syndrome characterised by a rapid decline in renal function and caused by a range of insults, including ischaemia‑reperfusion injury, sepsis, nephrotoxic drugs, hypovolaemia, major surgery and transplantation‑related injury. AKI is prone to progression to chronic kidney disease (CKD), and no effective treatment is currently available. Pyruvate dehydrogenase kinase 4 (PDK4), a regulator of mitochondrial metabolism, phosphorylates the E1α subunit of the pyruvate dehydrogenase (PDH) complex, thereby suppressing PDH enzymatic activity and limiting pyruvate oxidation. In renal tubular epithelial cells and other renal cell types, increased PDK4 mRNA expression and/or PDK4 protein abundance has been associated with enhanced inhibitory signalling through the PDK4‑PDH complex axis, typically reflected by increased phosphorylation of the PDH E1α subunit, reduced total PDH complex activity and suppressed mitochondrial pyruvate oxidation. These changes contribute to metabolic reprogramming, mitochondrial dysfunction, oxidative stress, inflammatory activation and cell death. Accumulating evidence suggests that PDK4‑mediated metabolic dysregulation contributes to tubular injury and maladaptive repair during AKI and the AKI‑to‑CKD transition, although its effects remain dependent on disease context and biological stage. The present review summarises the molecular regulation of PDK4, its pathological relevance in experimental AKI and the potential implications of PDK4 for therapeutic intervention and biomarker development. Moreover, the limited evidence supporting PDK4 as a candidate biomarker in AKI and the AKI‑to‑CKD transition is discussed. Although PDK4 protein is biologically linked to tubular metabolic stress and renal injury, its clinical biomarker performance has not yet been validated and further studies are required to determine its diagnostic and prognostic utility.

Authors

Institutions

Publication Details

Journal
Molecular Medicine Reports
Published
2026-11-18
DOI
https://doi.org/10.3892/mmr.2026.14075
Primary Topic
Acute Kidney Injury Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pyruvate dehydrogenase kinase 4 in acute kidney injury and the acute kidney injury‑to‑chronic kidney disease transition: A key metabolic regulatory hub and potential therapeutic target (Review)

Yufei Zhao, Lang Shi, Sen Zhou
1 links
Molecular Medicine Reports
Acute Kidney Injury Research
article

Pyruvate dehydrogenase kinase 4 in acute kidney injury and the acute kidney injury‑to‑chronic kidney disease transition: A key metabolic regulatory hub and potential therapeutic target (Review)

Yufei Zhao, Lang Shi, Sen Zhou
article en

Abstract

Acute kidney injury (AKI) is a common and heterogeneous clinical syndrome characterised by a rapid decline in renal function and caused by a range of insults, including ischaemia‑reperfusion injury, sepsis, nephrotoxic drugs, hypovolaemia, major surgery and transplantation‑related injury. AKI is prone to progression to chronic kidney disease (CKD), and no effective treatment is currently available. Pyruvate dehydrogenase kinase 4 (PDK4), a regulator of mitochondrial metabolism, phosphorylates the E1α subunit of the pyruvate dehydrogenase (PDH) complex, thereby suppressing PDH enzymatic activity and limiting pyruvate oxidation. In renal tubular epithelial cells and other renal cell types, increased PDK4 mRNA expression and/or PDK4 protein abundance has been associated with enhanced inhibitory signalling through the PDK4‑PDH complex axis, typically reflected by increased phosphorylation of the PDH E1α subunit, reduced total PDH complex activity and suppressed mitochondrial pyruvate oxidation. These changes contribute to metabolic reprogramming, mitochondrial dysfunction, oxidative stress, inflammatory activation and cell death. Accumulating evidence suggests that PDK4‑mediated metabolic dysregulation contributes to tubular injury and maladaptive repair during AKI and the AKI‑to‑CKD transition, although its effects remain dependent on disease context and biological stage. The present review summarises the molecular regulation of PDK4, its pathological relevance in experimental AKI and the potential implications of PDK4 for therapeutic intervention and biomarker development. Moreover, the limited evidence supporting PDK4 as a candidate biomarker in AKI and the AKI‑to‑CKD transition is discussed. Although PDK4 protein is biologically linked to tubular metabolic stress and renal injury, its clinical biomarker performance has not yet been validated and further studies are required to determine its diagnostic and prognostic utility.

Molecular Medicine ReportsVol. 35(1)
First Hospital of Lanzhou University (CN), Lanzhou University (CN)
Lanzhou University
Good health and well-being
Acute Kidney Injury Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon